Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial.
Authors: Ning Li, Di Wu, Yuan Fang, Yu Jiang, Xinhua Zhang, Wenna Liu, Xiaonan Sun, Pengxiang Wang, Yi Zhao